Dicot develops the potency drug of tomorrow

About our drug candidate

500 million men suffer from erectile dysfunction and premature ejaculation worldwide. Dicot is developing a modern potency drug with the ambition of creating a therapeutic drug that has a longer lasting effect and fewer side effects than those found on the market today.

News | 2024-01-23

First results from the clinical study out!

Part one in Dicot´s clinical phase 1-trial shows that LIB-01 has a very good safety profile. No serious adverse effects appeared and the drug is well absorbed in the body. 

Read More >

Dicot - the potency drug of tomorrow

News | 2023-11-24

Great interest for Dicot at North America's major sexual medicine congress

Dicot's CSO participated alongside Professor François Giuliano and sexual medicine expert Dr. Harin Padma-Nathan and experienced a lot of attention for our work. 

Read More >

The global market for treating sexual dysfunctions is annually worth around 7 billion USD and will increase due tu underlying causes such as growing number of elderly

Today's potency drugs were launched over twentyfive years ago and have limitations

Up to 35% of men with erection problems do not respond to current treatments. LIB-01 works differently and opens up the possibility of being helped

Existing drugs have a duration of action of maximum 36 hours. According to studies, LIB-01 can have an effect lasting at least seven days

Sexual medicine experts states that there is a great need for new potency drugs

In Sweden only one out of four seeks medical help for erectile dysfunction due to the condition's stigma

Pharmaceutical project

LIB-01 is now in clinical trials

Read More >

The ambition with LIB-01

  • Longer duration
  • Effective for everyone
  • Minimal side-effects
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 867137.